Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-86

[2] Soerjomataram I(2014)Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011 Cancer Res Treat 46 109-23

[3] Dikshit R(2006)Recommendations from an International Expert Panel on the use of neoadjuvant (Primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940-9

[4] Eser S(2006)Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019-27

[5] Mathers C(1998)Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 93-100

[6] Rebelo M(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483-93

[7] Jung KW(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-72

[8] Won YJ(2010)The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 1471-4

[9] Kong HJ(2013)Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer Ann Surg Oncol 20 2242-9

[10] Oh CM(2002)Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456-66

[1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 E359-86

[2] Soerjomataram I(2014)Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011 Cancer Res Treat 46 109-23

[3] Dikshit R(2006)Recommendations from an International Expert Panel on the use of neoadjuvant (Primary) systemic treatment of operable breast cancer: an update J Clin Oncol 24 1940-9

[4] Eser S(2006)Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019-27

[5] Mathers C(1998)Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute J Clin Oncol 16 93-100

[6] Rebelo M(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483-93

[7] Jung KW(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-72

[8] Won YJ(2010)The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM Ann Surg Oncol 17 1471-4

[9] Kong HJ(2013)Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer Ann Surg Oncol 20 2242-9

[10] Oh CM(2002)Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456-66